Newly approved ocular safety methods reduce animal testing (EurekAlert!)
Federal regulatory agencies have accepted recommendations of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) for two methods that can reduce live animal use for ocular safety testing, the committee announced today.
Newly Approved Ocular Safety Methods Reduce Animal Testing (Newswise)
Federal regulatory agencies have accepted recommendations of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) for two methods that can reduce live animal use for ocular safety testing, the committee announced today. ICCVAM is a permanent interagency committee composed of representatives from 15 federal regulatory and research agencies, including the ...
Market graduates from Loyola (New Orleans Times-Picayune)
The Crescent City Farmers Market, which started in 1995 as an offshoot of Loyola University, will enter a new phase Aug. 1 as an independent nonprofit organization.
Sirion Therapeutics Announces FDA Approval Of Durezol(TM) For Treatment Of Postoperative Ocular Inflammation And Pain (Medical News Today)
Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a topical steroid for the treatment of postoperative ocular inflammation and pain. The approval came after a six month priority review.
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain (PR Newswire via Yahoo! Finance)
Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved its new drug application for Durezol 0.05%, a topical steroid for the treatment of postoperative ocular inflammation and pain.
Alimera Reports Results From The Three-Month Interim Readout Of The Human PK Medidur(TM) FA Study (Medical News Today)
Alimera Sciences, Inc.
The heart and the drive (The Jewish Journal of Greater Los Angeles)
Hatschek Bela. The very sound of my great-grandfather's name brings a smile to my face.
Alimera reports positive interim results from Phase II macular edema trial (Pharmaceutical Business Review)
Alimera Sciences has reported the safety and efficacy results from the first human pharmacokinetic study of Medidur FA, which it intends to market under the tradename Iluvien, if approved by the FDA.
Newly Approved Ocular Safety Methods Reduce Animal Testing (Medical News Today)
Federal regulatory agencies have accepted recommendations of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) for two methods that can reduce live animal use for ocular safety testing, the committee announced.
pSivida Announces Interim Results From The Three-Month Readout Of The Human PK MedidurTM FA Study (Medical News Today)
Global drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FSE: PSI) today reported the interim three-month safety and efficacy results from the first human pharmacokinetic(1) (PK) study of Medidur™ FA, in patients with Diabetic Macular Edema (DME). This Phase II study is designed to support the ongoing pivotal Phase III clinical trial of Medidur in DME.
|
